Cartherics is frocking up this October to raise funds and awareness for crucial ovarian cancer research. The current five-year survival rate for ovarian cancer patients is just 49%. There is no early detection test and treatment options haven’t improved significantly in decades.

Cartherics’ Board Advisor and ovarian cancer survivor Heather Hawkins said, “As a survivor, I hope to see improvements in survival statistics. I’m optimistic about the future, especially with treatments like those from Cartherics, which promise to bring meaningful, positive change and enhance the lives of women globally.”

At Cartherics’ Frocktober event, Ovarian Cancer Research Foundation (OCRF) ambassador Kate Wyatt spoke about her experience with ovarian cancer and her role as an ambassador for the OCRF. Kate became an ambassador in 2023 and has thoroughly enjoyed this position. She hopes to enhance awareness and understanding of ovarian cancer in the community through her efforts.

As part of the ongoing fight against ovarian cancer, Cartherics’ lead cell therapy CTH-401 is a natural killer (NK) cell product designed to seek out and destroy the cells that cause ovarian cancer, with clinical trials planned for next year.

Cartherics’ CEO, Prof. Alan Trounson said, “We are intent on making a difference to women’s health in ovarian and breast cancer, as well as endometriosis. These events provide a meaningful way to connect with women facing these very challenging conditions.”